
<!DOCTYPE html>
<html>
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta http-equiv="X-UA-Compatible" content="ie=edge">
<title>Markmap</title>
<style>
* {
  margin: 0;
  padding: 0;
}
#mindmap {
  display: block;
  width: 100vw;
  height: 100vh;
}
</style>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/style.css">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.8/dist/katex.min.css">
</head>
<body>
<svg id="mindmap"></svg>
<script src="https://cdn.jsdelivr.net/npm/d3@7.8.5/dist/d3.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-view@0.17.0/dist/browser/index.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/index.js"></script>
<script>
window.WebFontConfig = {
  custom: {
    families: [
      "KaTeX_AMS","KaTeX_Caligraphic:n4,n7","KaTeX_Fraktur:n4,n7",
      "KaTeX_Main:n4,n7,i4,i7","KaTeX_Math:i4,i7","KaTeX_Script",
      "KaTeX_SansSerif:n4,n7,i4","KaTeX_Size1","KaTeX_Size2",
      "KaTeX_Size3","KaTeX_Size4","KaTeX_Typewriter"
    ],
    active: function() {
      window.markmap.refreshHook.call();
    }
  }
};
</script>
<script src="https://cdn.jsdelivr.net/npm/webfontloader@1.6.28/webfontloader.js" defer></script>
<script>
(() => {
  setTimeout(() => {
    const { markmap: Markmap, mm: markmapInstance } = window;
    const toolbar = new Markmap.Toolbar();
    toolbar.attach(markmapInstance);
    const toolbarElement = toolbar.render();
    toolbarElement.style.position = 'absolute';
    toolbarElement.style.bottom = '20px';
    toolbarElement.style.right = '20px';
    document.body.append(toolbarElement);
  });

  ((getMarkmap, getOptions, root, jsonOptions) => {
    const markmap = getMarkmap();
    window.mm = markmap.Markmap.create(
      "svg#mindmap",
      (getOptions || markmap.deriveOptions)(jsonOptions),
      root
    );
  })(() => window.markmap, null, {"content":"","children":[{"content":"HIGH RISK For Breast Cancer","children":[{"content":"No Germline mutation","children":[{"content":"IBIS Residual Lifetime Risk &gt;=20% and 10-year &gt;= 5%","children":[{"content":"Annual MMG and MRI (Minimum age 30 and 25 respectively)","children":[],"payload":{"lines":"4,5"}},{"content":"Chemoprevention with AI or Tamoxifen (20mg vs babytam)","children":[],"payload":{"lines":"5,6"}}],"payload":{"lines":"3,4"}},{"content":"IBIS Residual Lifetime Risk &gt;=20% and 10-year &lt; 5%","children":[{"content":"Annual MMG and MRI (Minimum age 30 and 25 respectively)","children":[],"payload":{"lines":"7,8"}}],"payload":{"lines":"6,7"}}],"payload":{"lines":"2,3"}},{"content":"Germline mutation","children":[{"content":"Management per mutation","children":[],"payload":{"lines":"9,10"}}],"payload":{"lines":"8,9"}}],"payload":{"lines":"1,2"}},{"content":"Noninvasive Breast Event","children":[{"content":"LCIS or ADH","children":[{"content":"Chemoprevention with AI or Tamoxifen (20mg vs babytam) IRRESPECTIVE of ER status","children":[],"payload":{"lines":"15,16"}}],"payload":{"lines":"14,15"}},{"content":"DCIS","children":[{"content":"ER+ve Mastectomy VERSUS BCS → RT → ET","children":[],"payload":{"lines":"17,18"}},{"content":"Adjuvant ET for contralat. chemoPPX. ET should be TAM (Pre) vs AI (Post) vs Tam 5mg PO qD x 3yr","children":[],"payload":{"lines":"18,19"}},{"content":"ER-ve Mastectomy VERSUS BCS → RT","children":[],"payload":{"lines":"20,21"}}],"payload":{"lines":"16,17"}}],"payload":{"lines":"13,14"}},{"content":"EARLY BREAST CANCER (I, II, III)","children":[{"content":"PREMENOPAUSAL HR POSITIVE HER2 NEGATIVE","children":[{"content":"pT1a N0\t\tDefinitive Surgery. [Role of ET?]","children":[],"payload":{"lines":"29,30"}},{"content":"pT1b-2 N0\tDefinitive Surgery → RS (ddAC/TC) → Adjuvant ET [TAM (pre) or AI (post)] x 5 years +/- 5 years (BCI)","children":[],"payload":{"lines":"30,31"}},{"content":"pT1-2 N1\t[Consider NACT] Definitive Surgery → RS (ddAC/TC) → Adjuvant ET (Ov Suppression if pre) x 5 years +/- 5 years (BCI)","children":[],"payload":{"lines":"31,32"}},{"content":"pT3-4 N0\t[Consider NACT] Definitive Surgery → TC OR ddAC/T [RS NOT validated] → Adjuvant ET x 5 years +/- 5 years (BCI).","children":[],"payload":{"lines":"32,33"}},{"content":"pT3 N1-3\t[Consider NACT] Definitive Surgery → ddAC/T [RS NOT validated] → Adjuvant ET (Ov Suppression if pre) x 5 years + 5 years.","children":[],"payload":{"lines":"33,34"}},{"content":"Based off TAILORx (Node NEG. 2018) RxPONDER (1 to 3 nodes. 2021)","children":[{"content":"N+ve","children":[{"content":"→ Chemotherapy irrespective of RS","children":[],"payload":{"lines":"36,37"}}],"payload":{"lines":"35,36"}},{"content":"N-ve","children":[{"content":"→ RS ≥26: Chemo.","children":[],"payload":{"lines":"38,39"}},{"content":"→ RS 16-25 : Discuss.","children":[],"payload":{"lines":"39,40"}},{"content":"→ ≤15 or less → no chemo","children":[],"payload":{"lines":"40,41"}}],"payload":{"lines":"37,38"}}],"payload":{"lines":"34,35"}},{"content":"Adjuvant Targeted therapies","children":[{"content":"OLAPARIB in high-risk ER+ HER2- gBRCA1/2 Stage II and III","children":[],"payload":{"lines":"42,43"}},{"content":"ABEMACICLIB in high risk patient: pN2/3 OR pN1 with either T3 OR Grade III","children":[],"payload":{"lines":"43,44"}}],"payload":{"lines":"41,42"}}],"payload":{"lines":"28,29"}},{"content":"POSTMENOPAUSAL HR POSITIVE HER2 NEGATIVE","children":[{"content":"pT1a N0\t\tDefinitive Surgery. [Role of ET?]","children":[],"payload":{"lines":"51,52"}},{"content":"pT1b-2 N0\tDefinitive Surgery → RS (ddAC/TC) → Adjuvant ET [TAM (pre) or AI (post)] x 5 years +/- 5 years (BCI)","children":[],"payload":{"lines":"52,53"}},{"content":"pT1-2 N1\t[Consider NACT] Definitive Surgery → RS (ddAC/TC) → Adjuvant ET (Ov Suppression if pre) x 5 years +/- 5 years (BCI)","children":[],"payload":{"lines":"53,54"}},{"content":"pT3-4 N0\t[Consider NACT] Definitive Surgery → TC OR ddAC/T [RS NOT validated] → Adjuvant ET x 5 years +/- 5 years (BCI).","children":[],"payload":{"lines":"54,55"}},{"content":"pT3 N1-3\t[Consider NACT] Definitive Surgery → ddAC/T [RS NOT validated] → Adjuvant ET (Ov Suppression if pre) x 5 years + 5 years.","children":[],"payload":{"lines":"55,56"}},{"content":"Based off TAILORx (Node NEG. 2018) RxPONDER (1 to 3 nodes. 2021)","children":[{"content":"Postmenopausal (Node + or -)\t→ RS ≥26: benefited from Chemo regardless of LNs","children":[],"payload":{"lines":"57,58"}}],"payload":{"lines":"56,57"}},{"content":"Adjuvant Targeted therapies","children":[{"content":"OLAPARIB in high-risk ER+ HER2- gBRCA1/2 Stage II and III","children":[],"payload":{"lines":"59,60"}},{"content":"ABEMACICLIB in high risk patient: pN2/3 OR pN1 with either T3 OR Grade III","children":[],"payload":{"lines":"60,61"}}],"payload":{"lines":"58,59"}}],"payload":{"lines":"49,50"}},{"content":"HR NEGATIVE HER2 POSITIVE","children":[{"content":"cT1a N0\t\tDefinitive Surgery (Role of Adj Anti HER2?)","children":[],"payload":{"lines":"65,66"}},{"content":"cT1b-1c N0\t\tDefinitive Surgery → Weekly Txl/Herceptin (APT) vs H alone (age 75+)","children":[],"payload":{"lines":"66,67"}},{"content":"cT12-4 OR N1-3\t\tTxr/Carbo/Herceptin/Perjeta NACT vs. TDM1/Perjeta → Definitive Surgery","children":[{"content":"No pCR\tTDM-1 to complete a year","children":[],"payload":{"lines":"68,69"}},{"content":"pCR\tHP to complete a year","children":[],"payload":{"lines":"69,70"}}],"payload":{"lines":"67,68"}}],"payload":{"lines":"64,65"}},{"content":"HR POSITIVE HER2 POSITIVE","children":[{"content":"cT1a N0\t\tDefinitive Surgery (Role of Adj Anti HER2?)","children":[],"payload":{"lines":"74,75"}},{"content":"cT1b-1c N0\t\tDefinitive Surgery → Weekly Txl/Herceptin (APT) vs H alone (age 75+) + TAM/AI/OFS+AI","children":[],"payload":{"lines":"75,76"}},{"content":"cT2-4 OR N1-3\t\tTxr/Carbo/Herceptin/Perjeta NACT vs. TDM1/Perjeta → Definitive Surgery","children":[{"content":"No pCR\tTDM-1 to complete a year + TAM/AI/OFS+AI","children":[],"payload":{"lines":"77,78"}},{"content":"pCR\tHP to complete a year + TAM/AI/OFS+AI → Neratinib + TAM/AI/OFS+AI","children":[],"payload":{"lines":"78,79"}}],"payload":{"lines":"76,77"}}],"payload":{"lines":"73,74"}},{"content":"HR NEGATIVE HER2 NEGATIVE","children":[{"content":"cT1a N0\t\tDefinitive Surgery (Role of Adj Chemotherapy?)","children":[],"payload":{"lines":"83,84"}},{"content":"cT1b-3 N1-3\t\tNACT Carbo/Txl/Pembro → ddAC / Pembro → Definitive Surgery","children":[{"content":"No pCR \tAdj. Pembro then Capecitabine (Standard 1250mg/m2 vs Metronomic 600mg/m2)","children":[],"payload":{"lines":"85,86"}},{"content":"pCR\t\tAdj. Pembro then Metronomic Cape. PARPi if HBOC (if very high risk)","children":[],"payload":{"lines":"86,87"}},{"content":"PARPi if HBOC","children":[],"payload":{"lines":"87,88"}}],"payload":{"lines":"84,85"}}],"payload":{"lines":"82,83"}}],"payload":{"lines":"25,26"}},{"content":"METASTATIC BREAST CANCER (IV)","children":[{"content":"PREMENOPAUSAL HR POSITIVE HER2 NEGATIVE","children":[{"content":"1st line","children":[{"content":"OFS+AI+CDK4/6 (Kisqali per MONALEESA-7)","children":[],"payload":{"lines":"99,100"}}],"payload":{"lines":"98,99"}},{"content":"2nd line","children":[{"content":"Soft progression → OFS / Faslo / Abema.","children":[],"payload":{"lines":"102,103"}},{"content":"PIK3CA mut → OFS / Faslo / Piqray.","children":[],"payload":{"lines":"103,104"}},{"content":"ESR1 mut → OFS / Elacestrant","children":[],"payload":{"lines":"104,105"}},{"content":"HBOC/sBRCA/gPALB2 → PARPi.","children":[],"payload":{"lines":"105,106"}},{"content":"Otherwise, OFS / Faslodex/Everolimus vs Enhertu (IHC 1+ or 2+ with Gp5)","children":[],"payload":{"lines":"106,107"}}],"payload":{"lines":"101,102"}},{"content":"3rd line","children":[{"content":"Enhertu (IHC 1+ or 2+ with Gp5) OR Chemotherapy","children":[],"payload":{"lines":"109,110"}}],"payload":{"lines":"108,109"}},{"content":"Further lines\tCHEMOTHERAPY","children":[],"payload":{"lines":"110,111"}}],"payload":{"lines":"94,95"}},{"content":"POSTMENOPAUSAL HR POSITIVE HER2 NEGATIVE","children":[{"content":"1st line","children":[{"content":"AI+CDK4/6. Consider holding CDK if low volume.","children":[],"payload":{"lines":"116,117"}}],"payload":{"lines":"115,116"}},{"content":"2nd line","children":[{"content":"Soft progression → Faslo / Abema.","children":[],"payload":{"lines":"118,119"}},{"content":"PIK3CA mut → Faslo / Piqray.","children":[],"payload":{"lines":"119,120"}},{"content":"ESR1 mut → Elacestrant","children":[],"payload":{"lines":"120,121"}},{"content":"HBOC/sBRCA/gPALB2 → PARPi. Otherwise, Faslodex/Everolimus","children":[],"payload":{"lines":"121,122"}}],"payload":{"lines":"117,118"}},{"content":"3rd line","children":[{"content":"Enhertu (IHC 1+ or 2+ with Gp5) OR Chemotherapy","children":[],"payload":{"lines":"123,124"}}],"payload":{"lines":"122,123"}},{"content":"Further lines\tCHEMOTHERAPY","children":[],"payload":{"lines":"124,125"}}],"payload":{"lines":"113,114"}},{"content":"HR NEGATIVE HER2 POSITIVE","children":[{"content":"1st line","children":[{"content":"Taxane/HP (vs Tr/HP) → maintenance HP","children":[],"payload":{"lines":"130,131"}}],"payload":{"lines":"129,130"}},{"content":"2nd lin","children":[{"content":"Enhertu vs Cape/Tucatinib/Herceptin","children":[],"payload":{"lines":"132,133"}}],"payload":{"lines":"131,132"}},{"content":"3rd line","children":[{"content":"Enhertu vs Cape/Tucatinib/Herceptin vs Margetuximab vs Cape/Neratinib","children":[],"payload":{"lines":"134,135"}}],"payload":{"lines":"133,134"}},{"content":"Further lines\tCHEMOTHERAPY","children":[],"payload":{"lines":"135,136"}}],"payload":{"lines":"128,129"}},{"content":"HR POSITIVE HER2 POSITIVE","children":[{"content":"1st line","children":[{"content":"Taxane / HP (vs Tr/HP) → maintenance HP + ET (OFS/AI vs AI)","children":[],"payload":{"lines":"140,141"}}],"payload":{"lines":"139,140"}},{"content":"2nd line","children":[{"content":"Enhertu vs Cape/Tucatinib/Herceptin vs Faslo / Abema / H","children":[],"payload":{"lines":"142,143"}}],"payload":{"lines":"141,142"}},{"content":"3rd line","children":[{"content":"Enhertu vs Cape/Tucatinib/Herceptin vs Margetuximab vs Cape/Neratinib","children":[],"payload":{"lines":"144,145"}}],"payload":{"lines":"143,144"}},{"content":"Further lines\tCHEMOTHERAPY","children":[],"payload":{"lines":"145,146"}}],"payload":{"lines":"138,139"}},{"content":"HR NEGATIVE HER2 NEGATIVE","children":[{"content":"1st line","children":[{"content":"Pembro (22C3 +ve) +/- Taxol/Abraxane/CarboGem","children":[],"payload":{"lines":"150,151"}},{"content":"Olaparib/Talzaporib (germline BRCA1/BRCA2 OR per TBCRC 048 gPALB2 OR somatic BRCA2)","children":[],"payload":{"lines":"151,152"}},{"content":"If not NGS, Paclitaxel (3 on 1 off)","children":[],"payload":{"lines":"152,153"}},{"content":"Capecitabine (Std vs low dose)","children":[],"payload":{"lines":"153,154"}},{"content":"Taxotere/Cytoxan","children":[],"payload":{"lines":"154,155"}}],"payload":{"lines":"149,150"}},{"content":"2nd line","children":[{"content":"Trodelvy","children":[],"payload":{"lines":"156,157"}},{"content":"Enhertu (IHC 1+ or 2+ with Gp5)","children":[],"payload":{"lines":"157,158"}},{"content":"CHEMOTHERAPY","children":[],"payload":{"lines":"158,159"}},{"content":"Consider Ixabepilone if progression on Adria and Taxane","children":[],"payload":{"lines":"159,160"}}],"payload":{"lines":"155,156"}},{"content":"3rd line","children":[{"content":"Trodelvy","children":[],"payload":{"lines":"161,162"}},{"content":"Enhertu (IHC 1+ or 2+ with Gp5)","children":[],"payload":{"lines":"162,163"}},{"content":"CHEMOTHERAPY","children":[],"payload":{"lines":"163,164"}},{"content":"Consider Halaven if progression on two prior chemotherapy agents","children":[],"payload":{"lines":"164,165"}}],"payload":{"lines":"160,161"}},{"content":"Further lines\tCHEMOTHERAPY","children":[],"payload":{"lines":"165,166"}}],"payload":{"lines":"148,149"}}],"payload":{"lines":"92,93"}},{"content":"LOCAL/REGIONAL RECURRENCE","children":[{"content":"ER POSITIVE: CALOR demonstrated no benefit in re-administration of Chemotherapy","children":[],"payload":{"lines":"171,172"}},{"content":"ER NEGATIVE: Modest benefit of rechallenge with chemotherapy","children":[],"payload":{"lines":"172,173"}}],"payload":{"lines":"170,171"}}]}, {"initialExpandLevel":3,"maxWidth":200});
})();
</script>
</body>
</html>
